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Abstract: INTRODUCTION Little data are available on anticoagulation (AC) management in patients
with cardiac resynchronization (CRT) devices who undergo transvenous lead extraction (TLE) procedure.
We investigated the impact of AC on periprocedural complications in CRT patients undergoing TLE,
enrolled in the ESC-EHRA European Lead Extraction ConTrolled (ELECTRa) registry. METHODS
AND RESULTS All CRT patients treated with TLE enrolled in the registry were considered. Periop-
erative AC management was left to the discretion of the Center. Major and minor intraprocedural and
postprocedural complications were compared between patients without AC (Gp1) and patients with AC
(Gp2). Regression analyses were performed to identify predictors of complications for Gp2. Out of 734
CRT pts, 328 (44.7%) were under AC (Gp2). Patients from Gp2 presented lower LVEF (Gp2 32.5 ± 10.9
vs Gp1 34.5 ± 11.9%; P = 0.03), more advanced heart failure disease (NYHA III/IV: Gp2 42.0 vs Gp1
31.5%; P = 0.02), and renal impairment (Gp2 39.0 vs Gp1 24.3%; P < 0.001). Perioperative regimens
included AC interruption (Gp2A: n = 169, 51.5%), ”bridging” (Gp2B: n = 135, 41.2%), or continued AC
(Gp2C: n = 24, 7.3%). TLE complete success rates (98% in both groups) and major complication rates
were comparable for both groups; minor bleeding events were more frequent in Gp2 (5.5%) compared
to Gp1 (2.5%; P = 0.051). No independent predictors were identified for Gp2, but minor complications
were associated with ”bridging” approach (Gp2B: 16 events vs Gp2A/C: 9 events; P = 0.020). CON-
CLUSION CRT patients treated with TLE under AC were more compromised but did not present more
major complications compared to patients without AC. More minor complications were associated with
”bridging” AC regimen.
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Abstract 
Introduction Little data are available on anticoagulation (AC) management in patients with 
cardiac resynchronization (CRT) devices who undergo lead extraction procedure (TLE). We 
investigated the impact of AC on peri-procedural complications in CRT patients undergoing 
TLE, enrolled in the ESC-EHRA European Lead Extraction ConTrolled (ELECTRa) registry.  
Methods and Results All CRT patients treated with TLE enrolled in the registry were 
considered. Peri-operative AC management was left to the discretion of the Center. Major and 
minor intra- and post-procedural complications were compared between patients without AC 
(Gp1) and patients with AC (Gp2). Regression analyses were performed to identify predictors of 
complications for Gp2.  
Out of 734 CRT pts, 328 (44.7%) were under AC (Gp2). Patients from Gp2 presented lower 
LVEF (Gp2 32.5±10.9 vs Gp1 34.5± 11.9%, p=0.03), more advanced HF disease (NYHA III/IV: 
Gp2 42.0 vs Gp1 31.5%, p=0.02), and renal impairment (Gp2 39.0 vs Gp1 24.3%, p<0.001). 
Perioperative regimens included AC interruption (Gp2A: n=169, 51.5%), “bridging” (Gp2B: 
n=135, 41.2%), or continued AC (Gp2C: n=24, 7.3%). TLE complete success rates (98% in both 
groups) and major complication rates were comparable for both groups; minor bleeding events 
were more frequent in Gp2 (5.5%) compared to Gp1 (2.5%, p=0.051). No independent predictors 
 














were identified for Gp2, but minor complications were associated with “bridging” approach 
(Gp2B: 16 events vs Gp2A/C: 9 events, p=0.020).  
Conclusion CRT patients treated with TLE under AC were more compromised, but did not 
present more major complications compared to patients without AC. More minor complications 
were associated with “bridging” AC regimen.  
Key words: lead extraction complications; CRT and lead extraction; anticoagulation in lead 
extraction; resynchronization therapy and complications; CRT and lead management.  
Introduction 
Cardiac resynchronization therapy (CRT) is a well-established non-pharmacological therapy for 
patients with heart failure. Compared to other cardiac implantable electronic devices CIEDs, 
CRT is a more complex device (one additional lead), usually has a shorter battery longevity, and 
is indicated in clinically complex patients (1), leading to more frequent replacement and possibly 
to higher infection rate. Furthermore, about 70% of CRT patients is fitted with a device that 
includes an implantable cardioverter-defibrillator (CRT-D) (1), thus more prone to mechanical 
stress resulting in more frequent lead dysfunction and local infection compared to a CRT with 
pacing function only (CRT-P). Should one of the above-listed clinical and technical issues arise 
in a given CRT patient then removal of the lead and/or device becomes mandatory. 
The recent European CRT Survey II (1) reported that at least 40% of CRT patients 
receive oral anticoagulants either with or without combination of oral antiplatelet therapy. 
Management of anticoagulation (AC) and/or antiplatelet therapy in CRT patients undergoing a 
transvenous lead extraction (TLE) has been investigated to a limited extent. Current 
recommendations by international scientific Societies are based on expert consensus and single 
experience from high-volume centers (2-4).  
 














The present study investigates the impact of anticoagulation therapy on intra- and peri-
procedural complications in CRT patients undergoing TLE and included in the prospectively 
designed, recently published ESC-EHRA ELECTRa registry (5). 
Methods 
Study design and patient population 
The present study represents a post-hoc analysis of CRT patients who underwent TLE and were 
included in the ELECTRa registry. Details about patient recruitment and data management have 
been extensively presented in a previous publication (5). The executive committee in co-
operation with the EURObservational Research Programme (EORP) provided the study design, 
protocol, and the scientific leadership of the registry under the responsibility of the EHRA 
Scientific Initiatives Committee. Ethics’ committee approval of the protocol was obtained for all 
participating centers and all subjects enrolled gave written informed consent to participate in the 
study. The investigation conformed with the principles outlined in the Declaration of Helsinki.  
Study objectives 
The primary objective was the comparison of cumulative incidence and rates of major 
intraprocedural and post-procedural complications including deaths, between patients never 
treated with AC therapy (Group 1) and those who had AC therapy (Group 2) before TLE (Figure 
1). This latter group of patients consisted of patients in whom AC was interrupted at TLE (Group 
2A), patients in whom AC was maintained with low weight molecular heparin (LWMH) (Group 
2B), and finally patients who maintained the same pre-operative AC (Group 2C). Secondary 
objectives included impact of AC therapy on minor complications, and the identification of 
specific predictors of any complication for Group 2.  
Peri-procedural anticoagulation management  
 














Peri-procedural anticoagulation management was not predefined by the registry protocol but left 
to physician’s discretion and center’s standard practice. Anticoagulation therapy included direct 
vitamin K antagonists (VKA), novel oral anticoagulants (non-VKA) which included dabigatran, 
rivaroxaban, or apixaban, and fractionated/unfractionated heparin.  
Definitions 
Definitions published in the guidance documents by EHRA and by HRS were used to define 
procedural approaches, techniques, and outcomes have been extensively reported in the main 
manuscript (5). In brief, sheaths were classified as mechanical non-powered (polypropylene or 
similar plastic material) or powered (laser, radio-frequency electrosurgical or controlled-
rotational with threaded tip devices). TLE safety and efficacy was analyzed by considering the 
rate of procedure related complications (major and minor) and success/failures (radiological and 
clinical). A major complication was defined as the one related to the procedure that was life 
threatening or resulted in death, or any unexpected event that caused persistent or significant 
disability, or any event that required significant surgical intervention. A radiological failure was 
defined when more than a 4 cm length of a lead was abandoned after a removal attempt, partial 
success when less than a 4 cm of a lead remained in the patient body and complete success when 
the lead was completely removed. Clinical failure (considered for each patient) was defined when 
either a procedure related major complication or a failure to achieve the clinical outcome for 
which the TLE was scheduled occurred. 
Statistics 
Univariate analysis was applied to both continuous and categorical variables. Continuous 
variables were reported as mean± standard deviation (SD) or as median and inter-quartile range 
(IQR). Among-group comparisons were made using a non-parametric test (Kruskal–Wallis test). 
Categorical variables were reported as percentages (without missing values if applicable). 
Among-group comparisons were made using a Chi-square test or the Fisher’s exact test. 
Comparative Kaplan Meier analysis was performed with Log Rank p determination to compute 
 














cumulative incidences of major adverse events and deaths. A stepwise multiple logistic 
regression was used to determine the predictors of any complication for Group 2 (variables with 
P<0.05 in univariate, except those with a high number of missing data). No interaction was 
tested. A two-sided p-value of 0.05 was considered as statistically significant. All the analyses 
were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA). 
Results 
Patient characteristics 
Out of the 3555 patients enrolled in the ESC-EHRA-EORP ELECTRa registry, 734 were CRT 
patients. Of these, 328 patients (44.7%, Group 2) were under chronic AC therapy, being the vast 
majority (67.1%) on vitamin K-antagonist (Figure 1). The demographic and clinical 
characteristics of Groups 1 and 2 are presented in Table 1, and were typical for a CRT patient 
cohort. Overall, there was a significant burden of co-morbidities represented by atrial fibrillation, 
diabetes, hypertension, renal and/or pulmonary insufficiency (Table 1). Importantly about 40% of 
the patients already experienced a previous lead or system revision. Patients who were on AC 
were older, had higher NYHA class, more frequently presented valvular heart disease and co-
morbidities (Table 1), but were however less treated with anti-platelet drugs. In contrast, 
indication to TLE, number of leads and dwelling time were similar between Groups 1 and 2); 
radiological success was nearly identical in the 2 main groups (Appendix, Table A-1). 
Peri-procedural anti-coagulation management 
For more than half of the CRT patients of Group 2 AC was interrupted (Group 2A, n=169, 
51.5%) with a median of 3 days (IQR 1-5 days), whereas AC interruption followed by “bridging” 
with fractionated (110 patients) or unfractionated heparin (25 patients) was performed in 135 
patients (Group 2B). In 24 patients (7.3%) TLE was performed under uninterrupted AC (Group 
2C) (Figure 1). 
 














Group 2C patients more often presented underlying valvular heart disease (Group 2C: 
45.8%, Group 2B: 26.7%, Group 2A: 22.9%, p=0.057) and less often dilated cardiomyopathy 
(Group 2C 41.7%, Group 2B 57.0%, Group 2A 73.1%, p<0.001). Furthermore, TLE indication 
was less often infective in Group 2C (Group 2C 50.0%, Group 2B 72.6%, Group 2A 66.3%, 
p=0.0791). Other characteristics between these 3 treatment groups are summarized in the 
Appendix, Table A-2. 
Primary objective 
A total of 29 major adverse events including 23 deaths occurred. The rates and cumulative 
incidences of the different major adverse events did not differ significantly between Groups 1 
and 2 (Table 2). Major complication event rates for Groups 2 and 1 were respectively (Table 2): 
intraprocedural rates were 0.3% (1 event) and 0.7% (p=0.427); post-procedural rates were 4.0% 
(13 events) and 3.0% (12 events, p=0.454); rates of death were 3.7% (n=12 events) and 2.7% 
(n=11 events, p=0.463). Cumulative incidences of death for any cause (Figure 2A) were 12.3% 
(95%CI 3.4-27.3%) and 10.1% (4.4-18.6%, Log Rank p=0.703), and for any major complication 
(Figure 2B) were 15.5% (95%CI 5.4-30.6%) and 13.9% (6.5-24.3%, Log Rank p=0.732), for 
Groups 2 and 1, respectively.  
Considering the different peri-operative AC treatment sub-groups, no differences were 
found in either the rates of intra- or postprocedural major complications or the rates of deaths. In 
the same way, cumulative incidences of any major complication or death did not differ between 
the three treatment groups (Figure 2C and 2D).  
Secondary objectives 
Even though the overall rate of minor complications did not differ between Group 2 (26 events, 
7.9%) and 1 (26 events, 6.4%, p=0.470), minor bleeding events however occurred more 
frequently in Group 2 (Table 2). Bleeding events requiring blood transfusions in the post-
procedural phase were significantly more frequently in Group 2 (6 events) compared to only 1 
 














event for Group 1 (p=0.028). Furthermore, surgical site hematoma events occurring mostly in the 
post-procedural phase were more frequent in Group 2 (8 events) compared to 3 events for Group 
1 (3 events, p=0.059).  
 When considering the different AC therapy regimens, Group 2B presented a significant 
higher rate of overall minor complications compared to the other strategies (Group 2B: 16 events 
[11.9%] vs Groups 2A/C: 9 events [4.7%], p=0.020). For Group 2B, all events occurred in the 
post-procedural phase. A greater number of venous thrombosis (n=4), minor bleedings requiring 
blood transfusions (n=5), and pocket hematoma occurred in this group (n=5), compared to 
Groups 2A/C (Table 3).  
Factors associated with any intra- or post-procedural complications in Group 2 (40 
events) identified at univariate analysis included TLE performed under general anesthesia (HR 
3.78, 95%CI 1.39-10.26, p=0.006) and laser-assisted technique (HR 2.36, 95%CI 1.16-4.79, 
p=0.018). NYHA class III revealed a trend in identifying patients at higher risk (HR 6.28, 95%CI 
0.81-48.71, p=0.065) of complications. At multivariate analysis, no independent predictors of any 
complication were identified for Group 2.  
Discussion 
To our knowledge, this is the first and largest study aiming to evaluate the effect of AC 
management on intra-procedural and post-procedural complications of CRT patients undergoing 
TLE. Several novelties are presented, all of which may have significant clinical consequences. 
The TLE complication risk was not different between CRT patients with or without a history of 
AC. Minor bleeding events were however observed more frequently in AC patients, but did not 
result in an excess of major events. CRT patients can be considered a particularly fragile patient 
group because of their clinical profile represented by significant comorbidity burden, anatomical 
challenges due to multiple leads with long dwelling time. While no increase of overall risk of 
major potentially lethal intra-procedural complications compared to patients with IPGs or ICDs 
(Figure 3). The post-procedural phase following TLE in CRT patients was characterized by high 
 














morbidity and mortality, regardless of whether the patients were under AC or not. Although these 
findings should be cautiously considered due to methodological limitations, these are reassuring 
as far as intra-procedural outcome is concerned, but warrant caution for post-procedural 
management. In considering different peri-procedural AC regimens, a significantly higher rate of 
minor post-procedural complications was observed when “bridging” strategy was performed. 
Avoiding this strategy is therefore advisable.  
Effect of chronic anti-coagulation therapy on intra- and postprocedural complication after TLE 
in CRT patients 
Anticoagulation indication in CRT patients is either stroke prevention of non-valvular atrial 
fibrillation, because of a prosthetic valve or, more rarely, due to deep venous thrombosis. TLE is 
considered a procedure which exposes patients to a high risk of major bleeding (4,6). However, 
thus far data specifically addressing the impact of anticoagulation on TLE outcomes in high risk 
patients, such as heart failure patients with CRT devices, are lacking.  
In the present study, despite the fact that CRT patients from the AC group were 
significantly more compromised in terms of heart failure disease and presented more frequently 
comorbidities, compared to their non-anticoagulated counterpart, major complications including 
deaths were comparable between the two groups. The rates of major intra-procedural and post-
procedural complications as well as deaths between the 2 groups were similar and roughly 0.5%, 
3.5%, and 3% respectively. Regardless of whether CRT patients were treated with AC or not, the 
rates of post-procedural complications were remarkably higher than the rates detected for all 
CIED in the whole ELECTRa patient cohort (5) (Figure 3). The fact that a significantly greater 
proportion of no AC patients were treated with anti-platelet drugs may in part account for the 
lack of excess of adverse events for AC patients in spite of their greater clinical complexity.  
Similar rates of major intra-procedural and peri-procedural complications (at one month) 
have been previously reported (7). In line with the present study, a smaller retrospective, 
multicenter experience (7) reported that localized bleeding, whether in the form of entry site 
 














bleeding requiring blood transfusion or pocket hematoma, represented the most frequent 
complication. In fact, the role of anticoagulation in determining increased bleeding events has 
been demonstrated in both studies. The study by Regoli and colleagues (7) identified 
anticoagulation therapy as an independent predictor of adverse events during the follow-up. 
Consistent with this finding, the present ELECTRa registry data showed that chronically 
anticoagulated CRT patients presented an overall rate of minor bleeding events more than 
twofold (5.6%) that of not anticoagulated patients (2.5%). 
Early pocket revision due to pocket hematoma significantly increases the risk of surgical 
site infection (8, 9), especially in patients with CRT-D devices (10). Measures to reduce the 
likelihood of pocket hematoma, including the positioning of a pocket drainage tube and a 
compressive medication are warranted. For patients at high risk of CIED infection use of the 
antibiotic pouch (11) is advised.  
Optimization of perioperative management of anti-coagulation therapy in CIED patients 
undergoing lead extraction 
Until now, there is little evidence in support of a specific anti-coagulation strategy for chronically 
anti-coagulated patients undergoing a lead extraction procedure. The recent 2017 Task Force 
document concludes that “… periprocedural anticoagulation strategies should be considered on a 
case-by-case basis, after assessing the thromboembolic risk during unprotected periods” (2). As 
outlined by an expert consensus document (4), careful clinical evaluation stratifying 
thromboembolic and bleeding risks in each patient is mandatory before any TLE procedure. 
However, these recommendations are not based on specifically designed controlled trials, but 
rather on expert consensus derived from single-center experiences of high-volume centers (3). 
This consensus, considers sub-therapeutic or therapeutic “bridging” with 
fractionated/unfractionated heparin in patients at high thromboembolic risk as a standard AC 
management strategy.  
 














The present study did observe, for the first time, an excess of minor bleeding events and, 
more importantly, of minor thromboembolic events associated with “bridging” AC strategy in the 
setting of TLE. This finding, coupled to the already well-known association between “bridging” 
approach and pocket hematoma during CIED de novo implantation or change (12), further 
strengthens the concept that “bridging” approach should be avoided altogether in periprocedural 
CIED management.  
In more than half of CRT patients under chronic anticoagulation, peri-procedural 
management approach consisted in interrupting the anti-coagulant three days before the 
procedure without “bridging”. Patients treated in this manner more frequently presented dilated 
cardiomyopathy, an infective indication for TLE, in whom device reimplant was more often 
deferred to another hospitalization. In this group, one out of every five patients were 
anticoagulated with a non-VKA anticoagulant (Appendix, Table A-2). The favourable 
pharmacodynamics of these anticoagulants as well as the recent availability of agents capable of 
reversing their effect, offer the advantage of controlling bleeding risk, while, at the same time, 
shortening the time in which the patient remains unprotected. These agents are now the therapy 
of choice for stroke prevention in patients with non-valvular atrial fibrillation and no or mild to 
moderate renal impairment. Since TLE is considered a procedure involving a high risk of major 
bleeding, current recommendations indicate non-VKA interruption 48 hours before the 
intervention and reinitiation not before 24 hours after (13). 
The few CRT patients treated according to the AC continued approach (Group 2C) 
presented several differences compared to the other 2 groups. These patients more often 
presented valvular heart disease, a non-infective indication for TLE, with device re-implantation 
performed during the same hospitalization (Appendix, Table A-2). Most of the CRT patients in 
this group are assumed to be those at highest thromboembolic risk. Although the number of 
patients treated through continued AC was limited, the overall incidences of major and minor 
complications were not higher compared to the other 2 groups. Similar findings have been 
recently reported by a large single-center experience (14). In this study, TLE was performed 
 














during uninterrupted warfarin therapy in patients at high risk of thromboembolic events with any 
CIED (5%, 62 patients of the entire consecutive cohort). TLE was highly successful and only one 
major complication was reported, namely femoral vein vascular tear needing surgical repair.  
   
Study limitations  
The present study is a retrospective analysis of data from the ELECTRa registry 
comparing early outcomes after TLE between CRT patients treated pre-operatively with 
anticoagulation and those not treated with anticoagulation. Some important differences between 
the groups, especially the fact that no AC patients were more often under anti-platelet drugs, and 
also the type of electrode extracted (the coronary sinus electrode was more often targeted for 
extraction in the AC group), the type of device reimplanted after extraction, may all have 
influenced the comparative analysis in a non-quantifiable way.  
The ELECTRa registry captures AC treatment strategies dating back a few years. Quite 
differently from what is reflected from the present registry data, most CRT patients with atrial 
fibrillation considered for TLE procedure are anticoagulated today with non-VKA 
anticoagulants.  
Conclusion  
Despite the fact that anticoagulated CRT patients were more compromised and fragile, TLE 
efficacy, cumulative incidences of periprocedural major complications and deaths, were all 
comparable to non-anticoagulated patients. The more frequent post-procedural minor bleeding 
events in anticoagulated patients, were mainly associated with the “bridging” approach. Until 
prospective, controlled clinical data for non-VKA anticoagulants become available, careful 
periprocedural anticoagulation management avoiding “bridging” anticoagulation strategy should 
continue to be the standard of practice.  
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Figure 1. ELECTRa registry patient flow diagram presenting the proportion of CRT 
patients of the total enrolled patient cohort of the registry and the proportion of the CRT 
patients under chronic anticoagulation therapy. For patients treated with peri-operative 
anticoagulation (Group 2) details are provided on the anticoagulation agent chronically 
prescribed as well as the peri-operative anticoagulation strategies implemented, either 
anticoagulation interrupted without bridging (Group 2A), “bridging” strategy (Group 2 B), or 
continued anticoagulation (Group 2 C). IPG: implantable pulse generator; ICD: implantable 
cardioverter defibrillator; CRT-D/P: Cardiac resynchronization therapy defibrillator (D) or 
pacemaker (P); VKA: Vitamin K antagonist; LMWH: low-molecular weight heparin; Non-















- VKA: 230 patients
- LMWH: 35 patients
- i.v. Heparin: 9 patients





























Figure 2. Comparison of freedom from death for any cause after lead extraction between 
Group 1 (blue curve, no AC) and Group 2 (red curve, on AC), and between subgroups 2A 
(yellow, AC interrupted), 2B (red, AC bridging), and 2C (blue, AC continued) are presented in 
panels A and C, respectively. Comparison of freedom from major complications after lead 
extraction between Groups 1 and 2 and between subgroups 2A, 2B, and 2C are presented in 
panels B and D, respectively. Values are expressed as absolute and as percentage cumulative 
























Figure 3. Overall major and minor intra-procedural (Panel A) and post-procedural 
complication rates (Panel B) are presented for all groups, including the anticoagulation patient 
subgroups, 2A, 2B, and 2C. On the right of each panel corresponding overall intraprocedural 
(Panel A) and post-procedural (Panel B) complication rates of the complete ELECTRa registry 




























All Group 1 Group 2 Group 2A Group 2B Group 2C
ELECTRa cohort
(All)
Major complications 0.5 0.7 0.3 0 0.7 0 1.1






















A. Intra-procedural complication rate
All Group 1 Group 2 Group 2A Group 2B Group 2C
ELECTRa cohort
(All)
Major complications 3.9 3.7 4.2 4.7 3 4.2 0.6
























B. Post-procedural complication rate
Figure 3. 
 














Table 1. Demographic and peri-procedural characteristics.  
Variable  Total (N=734) 
Not treated with 
AC (N=406) 
(Group 1) 
Treated with AC 
(N=328) 
(Group 2) p-value 
Demographic and clinical      
Age (years)  68.1 (11.3) 67.4 (11.5) 68.9 (11.1) 0.091 
Gender (Male) Male 602 (82.0) 328 (80.7) 274 (83.5) 0.335 
Body Mass Index (kg/m2)  27.0 (4.6) 27.3 (4.6) 26.7 (4.7) 0.037 
Heart Disease Etiology  









 Valvular heart disease  125 (17.1) 40 (9.9) 85 (26.2) <0.001 
 Dilated cardiomyopathy  495 (67.7) 286 (70.6) 209 (64.1) 0.061 
 Other heart disease  18 (2.4) 8 (1.9) 10 (3.0) 0.347 
NYHA I 60 (8.3) 37 (9.3) 23 (7.1) 0.016 
 II 312 (43.2) 187 (47.1) 125 (38.5)  
 III 246 (34.1) 122 (30.7) 124 (38.2)  
 IV 20 (2.7) 6 (1.5) 14 (4.3)  
Left Ventricular Ejection Fraction 
(%) 
 33.57 (11.5) 34.45 (11.9) 32.49 (10.9) 0.029 
Hypertension  433 (59.8) 243 (60.7) 190 (58.6) 0.565 
Diabetes mellitus  247 (34.1) 137 (34.5) 110 (33.7) 0.829 
Chronic kidney disease  226 (30.9) 98 (24.3) 128 (39.0) <0.001 
Chronic obstructive pulmonary 
disease 
 91 (12.4) 49 (12.1) 42 (12.8) 0.780 
Implanted device history      
Device type CRT-pacemaker  127 (17.3) 69 (17.0) 58 (17.6) 0.806 
CRT-defibrillator  607 (82.7) 337 (83.0) 270 (82.3) 0.806 
Previous complications to CIED  254 (34.6) 146 (35.9) 108 (32.9) 0.390 
Previous system revisions 0 460 (63.6) 251 (63.0) 209 (64.3) 0.586 
 1 166 (22.9) 90 (22.6) 76 (23.3)  
 2 55 (7.6) 32 (8.0) 25 (7.7)  
 ≥3 40 (5.5) 25 (6.3) 15 (4.6)  
Previous attempt of lead extraction  30 (4.1) 19 (4.7) 11 (3.4) 0.366 
Antiplatelet therapy      
Aspirin  323 (44.0) 240 (59.1) 83 (25.3) <0.001 
Clopidogrel  46 (6.3) 32 (7.9) 14 (4.3) 0.045 
Prasugrel  5 (0.7) 4 (1.0) 1 (0.3) 0.265 
Ticagrelor  1 (0.1) 1 (0.2) 0 0.368 
Dual anti-platelet  28 (3.8) 22 (5.4) 6 (1.8) 0.012 
Other  11 (1.5) 10 (2.5) 1 (0.3) 0.017 









 median [IQR], days   3.00 [1.00- 5.00] NA 3.00 [1.00- 5.00]  
Bridging LMWH  101 (74.8) NA 101 (74.8)  
 Heparin iv.   25 (18.5) NA 25 (18.5)  
 Unknown   9 (6.6) NA 9 (6.6)  
Continued  24 (7.3) NA 24 (100)  
Medication Vitamin K antagonist  230 (70.1) NA 230 (70.1)  
 LMWH  35 (10.7) NA 35 (10.7)  
 Heparin  9 (2.7) NA 9 (2.7)  
 Non-VKA  54 (16.5) NA 54 (16.5)  
 














Continuous variables are expressed as mean with corresponding standard deviation or median 
with corresponding IQR; categorical variables are expressed as absolute value with proportion 
between parenthesis. NYHA: New York Heart Association Class; LMWH: low molecular weight 
heparin; NA: not applicable; Non-VKA: Non-vitamin K-antagonist.  
 
Table 2. Comparison of complications and deaths between CRT patients not treated with AC 
(Group 1) and treated with AC (Group 2).  
 







(Group 1) (Group 2) 
Intra- and post-procedural complications         
MAJOR- total 29 (3.9) 15 (3.7) 14 (4.2) 0.692 
Intraprocedural 4 (0.5) 3 (0.7) 1 (0.3) 0.427 
 Death  2 2 0 0.203 
 Cardiac avulsion or tear  1 1 0 0.368 
 Vascular avulsion or tear  2 2 0 0.203 
 Respiratory or anesthesia  1 0 1 0.261 
Post-procedural 25 (3.4) 12 (3.0) 13 (4.0) 0.454 
 Death  21 9 12 0.244 
 Cardiac avulsion or tear  2 1 1 0.880 
 Vascular avulsion or tear  2 0 2 0.115 
 Stroke  1 0 1 0.266 
 Respiratory or anesthesia  2 2 0 0.203 
 














Total major bleeding 7 4 3 1.000 
Total major thromboembolic 1 0 1 1.000 
MINOR-total 52 (7.1) 26 (6.4) 26 (7.9) 0.465 
Intraprocedural 7 (1.0) 4 (1.0) 3 (0.9) 0.922 
 Hematoma at surgical site req. reop. or drainage  1 1 0 0.368 
 Blood transfusion 3 1 2 0.443 
 Pulmonary embolism not req. surgery  1 1 0 0.368 
 Arrythmias 2 1 1 0.880 
Post-procedural 45 (6.1) 22 (4.1) 23 (7.0) 0.440 
 Pericardial effusion without drainage 4 3 1 0.427 
 Hemotorax without chest tube 1 0 1 0.266 
 Hematoma at surgical site req. reop.  
 or drainage  
11 3 8 0.059 
 Blood transfusion 7 1 6 0.028 
 Pneumothorax req. chest tube 3 3 0 0.119 
 Pulmonary embolism not req. surgery  2 1 1 0.880 
 Vein thrombosis 9 5 4 0.761 
 Vascular repair near the implant site 1 1 0 0.368 
 Arrythmias 5 4 1 0.071 
 Other 2 1 1 0.265 
 














Total minor bleeding 28 10 18 0.051 
Total minor thromboembolic 12 7 5 1.000 
Continuous variables are expressed as mean with corresponding standard deviation or median 
with corresponding IQR; categorical variables are expressed as absolute value with proportion 






Table 3. Comparison of minor complications between the “bridging” and the other two peri-
procedural anticoagulation strategies. 
 






MINOR- Total  9 (4.7) 16 (11.9) 0.020 
Intraprocedural 3 (1.6) 0 0.271 
 Arrhythmia 1 0 1.000 
 Blood transfusion 2 0  0.514 
Post-procedural 6 (3.1) 16 (11.9) 0.005 
 Pericardial effusion without drainage 0 1  0.412 
 Hematoma at surgical site req.  
 intervention  
3 5  0.281 
 Hemotorax without chest tube 1  0   1.000 
 Vein thrombosis 0 4  0.028 
 Blood transfusion 1 5  0.087 
 Pneumothorax req. chest tube 0 0 1.000 
 Pulmonary embolism not req.  
 surgery 
0 1  0.412 
 Other  1 0 1.000 
Total minor bleeding  7 (3.6) 11 (8.1) 0.088 
Total minor thromboembolism 0 5 (3.7) 0.011 
Continuous variables are expressed as mean with corresponding standard deviation or median 
with corresponding IQR; categorical variables are expressed as absolute value with proportion 
between parenthesis.  
 
